First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection.
Linlin LiQiu ZhongYunze ZhaoJuan BaoBing LiuZhuojun ZhongJing WangLan YangTingting ZhangMengjun ChengNannan WuTong-Yu ZhuShuai LePublished in: Microbial biotechnology (2023)
A double-stranded RNA (dsRNA) phage phiYY is able to kill a pyomelanin-producing Pseudomonas aeruginosa strain, which was isolated from a 40-year-old man with interstitial lung disease (ILD) and chronic lung infection. Phage therapy was used as a last resort for this patient. The three-course nebulized phiYY treatment was used to reduce the bacterial burden and clinical symptoms of the patient. Recurrences of P. aeruginosa infections were observed 1-3 days post phage therapy. The recurrent isolates exhibited distinct antibiotic-susceptibility profiles compared with the original strain yet were still susceptible to phiYY. This assay represents the application of dsRNA phage in the treatment of chronic lung infection, albeit the safety and efficacy of the dsRNA phage require further assessment.
Keyphrases
- pseudomonas aeruginosa
- interstitial lung disease
- cystic fibrosis
- biofilm formation
- systemic sclerosis
- endothelial cells
- acinetobacter baumannii
- rheumatoid arthritis
- pulmonary hypertension
- high throughput
- case report
- staphylococcus aureus
- escherichia coli
- physical activity
- binding protein
- mesenchymal stem cells
- bone marrow
- nucleic acid
- multidrug resistant
- single cell
- sleep quality
- pluripotent stem cells